We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Newly Identified Biomarkers to Pave Way for SIDS Screening Test

By LabMedica International staff writers
Posted on 13 Sep 2024

Approximately 1,300 infants under the age of one die each year from sudden infant death syndrome (SIDS), and researchers still do not fully understand the causes of these unexpected deaths. More...

It is known that multiple factors are likely contributors, including inadequate prenatal care, maternal smoking and alcohol use during pregnancy, structural racism, and air pollution. Male infants have a higher incidence of SIDS compared to females. Scientists are now turning to biological factors in the search for a cause of SIDS that could be identified at birth or targeted with medication. In a new study, researchers have identified signals within the metabolic systems of infants who died from SIDS and believe these metabolic indicators could be key in reducing mortality. While more research is needed, this discovery could one day help prevent SIDS.

In the study, investigators at UC San Francisco (San Francisco, CA, USA) drew on previous research suggesting that the metabolic system—which involves how bodies process and store energy—might play a role in SIDS. They decided to examine this system more closely by comparing metabolic data from infants collected during routine newborn screenings in California. They contrasted the data of infants who eventually died from SIDS with that of similar infants who survived. Among the 354 infants who died from SIDS, they found certain metabolic biomarkers that may be associated with an increased risk. For example, infants with lower levels of C-3 and higher levels of C-14OH appeared to have a greater risk of dying from SIDS. These findings, published in JAMA Pediatrics, are consistent with previous research linking enzymes involved in fatty acid oxidation to SIDS. The scientists also discovered several other biomarkers that, when elevated, seemed to correlate with a reduced risk of SIDS.

The research remains preliminary, and the scientists emphasized the need for validation in additional settings. While this study was conducted using records of infants who had already passed away, the authors noted that it would be ideal to study living infants and follow them as they develop. Although the ultimate goal of creating a screening test for SIDS is still distant, this development indicates the potential for future breakthroughs in preventing this devastating syndrome. The research team plans to next explore other metabolic markers and their genetic counterparts to see if they can identify even more factors contributing to SIDS.

"This study suggests that metabolic factors may play a crucial role in SIDS,” said Scott Oltman, MS, an epidemiologist at UCSF and first author of the study. “These patterns could help identify children at higher risk, potentially saving lives in the future. This study is a critical step toward integrating metabolic markers with potential genetic markers and other risk factors to better assess the risk of SIDS in infants."

Related Links:
UC San Francisco


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
New
Slide Scanner System
NanoZoomer S540MD
Gold Member
Platelet Function Analyzer
PL-12
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Two major international studies identified noninvasive tests that can accurately diagnose and assess MASLD and MASH, reducing reliance on liver biopsy. (Image Credit: Adobe Stock)

Noninvasive Tests Offer Alternatives to Biopsy for Assessing Advanced Liver Scarring

Metabolic dysfunction-associated steatotic liver disease (MASLD) affects up to one in three adults worldwide and as many as seven in 10 people with obesity or type 2 diabetes. Its more severe form, metabolic... Read more

Hematology

view channel
Image: Mayo Clinic researchers used genetic data from nearly 50,000 participants to identify sickle cell and beta-thalassemia carrier traits, highlighting how population-scale testing can complement existing screening (Image Credit: Adobe Stock)

Genetic Testing Offers Opportunities for Earlier Blood Disorder Carrier Identification

Inherited hemoglobin disorders can affect oxygen transport, yet individuals who carry only a trait may remain unaware of their status. People with sickle cell trait or beta-thalassemia trait often have... Read more

Microbiology

view channel
Image: Graphical Abstract (Andrew Medina-Marino, Chibuzor M Babalola, Mandisa M Mdingi, et al. Clinical Infectious Diseases, 2026. doi:10.1093/cid/ciag577.)

Repeat Prenatal STI Screening and Treatment May Reduce Preterm Births

Preterm birth remains a major obstetric concern and is associated with serious complications in early childhood. Common sexually transmitted infections during pregnancy often cause no symptoms, making... Read more

Pathology

view channel
Image Credit: Adobe Stock

AI Pathology Approach Closely Aligns With Breast Cancer Genomic Risk Classification

In early-stage breast cancer, precision oncology relies on biological information to guide personalized treatment decisions. Because access to tissue-based genomic testing may be limited, there is growing... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.